Search - tctmd.com

Displaying 1 - 20 of 62

Sort: Relevancy | Date

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

L.A. McKeown

September 05, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

News Daily News

New Scientific Statement Focuses on Below-the-Knee Technical Challenges

L.A. McKeown

January 19, 2024

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

L.A. McKeown

June 09, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

Advertisement

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

Top Endovascular News of 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

New Scientific Statement Focuses on Below-the-Knee Technical Challenges

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Worse Complications After PVI in Women Highlight Research Gaps

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

Routine IVUS in Peripheral Interventions Supported by Small RCT

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content